Rayno Life Science Portfolio Tools and Dx-Big Winners YTD: CRA,CSII,EXAS,GPRO
Diagnostics is Still a Hot Ticket The Rayno Life Science Tools and Diagnostics Portfolio is up 12% YTD with big winners Celera up 31%, recently acquired by Quest Diagnostics (DGX), Cardiovascular Systems (CSII) up 32.5%,Exact Scientific (EXAS) up 42%, and GenProbe (GPRO) up 19.6%. In the news...
Rayno Life Science Portfolio Tools and Dx: Immucor (BLUD) Up 30% on Buyout
TPG Capital Offers $1.97B for diagnostic Company focused in blood donor screening. TPG Capital is a private equity firm with $48B in assets. Immucor was added to the Rayno Life Science Portfolio in April 2010 at a price of...
Rayno Life Science Portfolio 2011 H1 Update-Biopharm Big Winners:BIIB, CBST, REGN, SGEN
2011 A Huge Year for Life Science Investing As of mid-year the Rayno Life Science Biopharmaceutical Portfolio was up over 20% beating most ETF's and Life Science mutual funds. Our two recommended biotech ETF's for balancing and overweighting were FBT up 13.3% and IBB up 15.3%. Returns could...
Trends From BIO International Conference: Biotech Sector Performance YTD,MTD
The 2011 Bio Meeting was well attended surpassing last year's number around 15,000. International participation continues to grow with 37% of attendees outside of the U.S. Virtually every country that has industry and universities is looking at biotech development (BIO will release official...
BIO International Convention This Week June 27-30; News on AMGN,GILD
We will be attending the BIO Meeting in Washington DC and will not be posting as usual. Note that there were two news items over the weekend on our portfolio stocks: A positive article on Gilead (GILD) in Barron's. Gilead Sciences Shares Could Rally - Barrons.com Another article in Barron's...